Daksh Thaper
Daksh Thaper
University of British Columbia
Verified email at prostatecentre.com
Title
Cited by
Cited by
Year
The master neural transcription factor BRN2 is an androgen receptor suppressed driver of neuroendocrine differentiation in prostate cancer
JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ...
Cancer discovery, CD-15-1263, 2017
1512017
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo
C Thomas, F Lamoureux, C Crafter, BR Davies, E Beraldi, L Fazli, S Kim, ...
Molecular cancer therapeutics 12 (11), 2342-2355, 2013
1052013
The multifaceted roles of STAT3 signaling in the progression of prostate cancer
JL Bishop, D Thaper, A Zoubeidi
Cancers 6 (2), 829-859, 2014
872014
Hsp27 regulates EGF/β‐catenin mediated epithelial to mesenchymal transition in prostate cancer
T Cordonnier, JL Bishop, M Shiota, KM Nip, D Thaper, S Vahid, D Heroux, ...
International journal of cancer 136 (6), E496-E507, 2015
522015
The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017; 7: 54–71. doi …
JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ...
Mechanistic link between AR and the master regulator of neuronal …, 0
34
Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth
A Takeuchi, M Shiota, E Beraldi, D Thaper, K Takahara, N Ibuki, M Pollak, ...
Molecular and cellular endocrinology 384 (1-2), 117-125, 2014
312014
Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer
S Vahid, D Thaper, KF Gibson, JL Bishop, A Zoubeidi
Scientific reports 6 (1), 1-12, 2016
282016
SEMA 3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1
JW Peacock, A Takeuchi, N Hayashi, L Liu, KJ Tam, N Al Nakouzi, ...
EMBO molecular medicine 10 (2), 219-238, 2018
242018
Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer
A Zardan, KM Nip, D Thaper, P Toren, S Vahid, E Beraldi, L Fazli, ...
Oncogenesis 3 (8), e115-e115, 2014
212014
Targeting Lyn regulates Snail family shuttling and inhibits metastasis
D Thaper, S Vahid, KM Nip, I Moskalev, X Shan, S Frees, ME Roberts, ...
Oncogene 36 (28), 3964-3975, 2017
182017
Chaperoning the cancer: The proteostatic functions of the heat shock proteins in cancer
S Vahid, D Thaper, A Zoubeidi
Recent patents on anti-cancer drug discovery 12 (1), 35-47, 2017
162017
Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
D Thaper, S Vahid, R Kaur, S Kumar, S Nouruzi, JL Bishop, M Johansson, ...
Scientific reports 8 (1), 1-9, 2018
112018
PEG10 is associated with treatment-induced neuroendocrine prostate cancer
S Kim, D Thaper, S Bidnur, P Toren, S Akamatsu, JL Bishop, C Colins, ...
Journal of molecular endocrinology 63 (1), 39-49, 2019
102019
Reduction in PD-L1 expression by STAT3 inhibition with GPA500 in enzalutamide-resistant prosate cancer.
JL Bishop, DL Thaper, S Vaheid, MH Johansson, A Zoubeidi
Journal of Clinical Oncology 33 (15_suppl), e16075-e16075, 2015
32015
First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer
D Thaper, R Munuganti, S Nouruzi, S Kumar, S Kim, O Sivak, A Aguda, ...
Cancer Research 79 (13 Supplement), 1295-1295, 2019
12019
Neural Transcription Factors in Disease Progression
D Thaper, S Vahid, A Zoubeidi
Prostate Cancer, 437-462, 2019
12019
New derivative of galiellalactone inhibits the STAT3 activity and suppresses ENZ-resistant Prostate Cancer in vitro
D Thaper, S Vahid, JL Bishop, M Johansson, A Zoubeidi
Cancer Research 75 (15 Supplement), 728-728, 2015
12015
Regulation of PPARγ expression in luminal muscle invasive bladder cancer
D Tortora, R Morgan, G Kumar, E Ritch, B McConeghy, S Sinha, ...
Urologic Oncology: Seminars and Original Investigations 38 (12), 905, 2020
2020
Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of cisplatin sensitivity in muscle-invasive bladder cancer
G Kumar, E Ritch, HZ Oo, CK Wang, D Tortora, D Thaper, I Moskalev, ...
Urologic Oncology: Seminars and Original Investigations 38 (12), 905, 2020
2020
Selective inhibition of transcription factor BRN2 as a treatment strategy for Small Cell Prostate Cancer
D Thaper, R Munuganti, A Aguda, S Kim, S Ku, S Kumar, S Vahid, ...
Cancer Research 80 (16 Supplement), 3083-3083, 2020
2020
The system can't perform the operation now. Try again later.
Articles 1–20